ライフサイエンスコーパス: factor II

1 methyl-isobacteriochlorin (Ni(II) and Zn(II)-factor-II).

2 III) 2,7-dimethyl-isobacterioclorin (Co(III)-factor-II).

3 f growth factors such as insulin-like growth factor II.

4 tion factor, cleavage factor I, and cleavage factor II.

5 en ovalbumin upstream promoter transcription factor II.

6 n is porcine alveolar macrophage chemotactic factor-II.

7 ther with TBP comprise general transcription factor IID.

8 on factor, IIB, in addition to transcription factor IID.

9 ranscript shortening action of transcription factor IIS.

10 olecules and TATA-binding protein-associated factor II 110.

11 chain reaction for factor V 1691A (Leiden), factor II 20 210A, methylenetetrahydrofolate reductase 6

12 active site-inhibited factor IXa (4 nM) and factor II (4 microM), factor X binds to 3-fold more plat

13 actor X/factor II site was blocked by excess factor II (4 microM).

14 ntrols the production of insulin-like growth factor II, an autocrine inducer of differentiation, thro

15 cant associations with relatively minor risk factors; (ii) analysis of multiple candidate genes in gr

16 rve 3/4-restricted genes insulin-like growth factor II and guanine deaminase protected spinal motor n

17 as been shown in vitro to insert cobalt into factor II and may have evolved to support B12 synthesis

18 proteins such as undercarboxylated forms of factor II and osteocalcin to assess tissue and functiona

19 ts are defective in insertion of cobalt into factor II and that the Salmonella CysG enzyme normally c

20 owth regulators, such as insulin-like growth factor II and the insulin-like growth factor I receptor.

21 eficient in secretion of insulin-like growth factor II and their defect can be complemented with exog

22 interactions of sex with insulin-like growth factor-II and insulin for whole-body protein synthesis.

23 warfarin monitoring method affected only by factors II and X (Fiix-prothrombin time [Fiix-PT]) compa

24 o contiguous IGF2 (human insulin-like growth factor II) and H19 genes are reciprocally imprinted in b

25 precorrin-2), ring oxidation (precorrin-2 to factor II), and iron insertion (factor II to siroheme).

26 (TATA-binding protein), TFIIS (transcription factor IIS), and a number of chromatin remodeling factor

27 CRD-BP), binds to c-myc, insulin-like growth factor II, and beta-actin mRNAs, and to H19 RNA.

28 en ovalbumin upstream promoter-transcription factor II, and the peroxisome proliferator-activated rec

29 en ovalbumin upstream promoter transcription factor II, and transcription is diminished.

30 in-like growth factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protei

31 in-like growth factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protei

32 en ovalbumin upstream promoter transcription factor II (ARP-1/COUP-TFII) and retinoid X receptor (RXR

33 The data identify insulin-like growth factor II as one developmentally important protein whose

34 ulating TAF9 deacetylation and transcription factor IID assembly.

35 The general transcription factor II B (TFIIB) plays a central role in both the ass

36 F1) and the tilapia homolog of transcription factor II B (TFIIB), that are rapidly and transiently in

37 Similarly, the recruitment of transcription factor II B and RNA polymerase II to the gamma promoter

38 in-like growth factor 1, insulin-like growth factor II, basic fibroblast growth factor, platelet-deri

39 oding the p44 subunit of basal transcription factor II (BTF2p44).

40 osphate receptor and the insulin-like growth factor II/cation-independent mannose 6-phosphate recepto

41 eceptor (CD-MPR) and the insulin-like growth factor II/cation-independent mannose 6-phosphate recepto

42 ent MPR (CD-MPR) and the insulin-like growth factor II/cation-independent MPR, carry out this process

43 r interacted directly with the transcription factor IID components hTAF(II)130 and TATA box-binding p

44 of the ring could then constrain the metallo-factor-II conformation toward that of the usual substrat

45 are stabilized by knockdown of transcription factor IIS, consistent with a requirement for RNA polyme

46 e shown that Pol II and TFIID (transcription factor IID) contact overlapping regions of the promoter,

47 ciated with the formation of a transcription factor IID-containing complex on an initiator sequence l

48 en ovalbumin upstream promoter-transcription factor II (COUP-TFII) has been shown to inhibit myogenes

49 en ovalbumin upstream promoter-transcription factor II (COUP-TFII) hyperactivity as a contributing fa

50 en ovalbumin upstream promoter transcription factor II (COUP-TFII) in a dose-dependent manner.

51 en Ovalbumin Upstream Promoter-Transcription Factor II (COUP-TFII) in Leydig cell (LC) steroidogenesi

52 en ovalbumin upstream promoter transcription factor II (COUP-TFII) in the regulation of renin gene ex

53 en Ovalbumin Upstream Promoter-Transcription Factor II (COUP-TFII) is an important coordinator of glu

54 en ovalbumin upstream promoter transcription factor II (COUP-TFII) is the predominant nuclear recepto

55 en ovalbumin upstream promoter-transcription factor II (COUP-TFII) promoter that binds to a factor di

56 and chicken ovalbumin upstream-transcription factor II (COUP-TFII) that promote or inhibit divergent

57 eas chicken ovalbumin upstream transcription factor II (COUP-TFII) was decreased 40% at 16 hours.

58 en ovalbumin upstream promoter-transcription factor II (COUP-TFII), a member of the nuclear receptor

59 en ovalbumin upstream promoter-transcription factor II (COUP-TFII), a member of the nuclear receptor

60 en ovalbumin upstream promoter transcription factor II (COUP-TFII).

61 en ovalbumin upstream promoter transcription factor II (COUP-TFII, also known as Nr2f2) is required f

62 Here we show that COUP transcription factor II (COUP-TFII, also known as NR2F2), a member of

63 en ovalbumin upstream promoter-transcription factor II (COUP-TFII; Nr2f2) is expressed in adipose tis

64 t of TAF proteins is shared in transcription factor II D (TFIID) and SAGA transcription regulatory co

65 factors (TAFs) that constitute transcription factor II D (TFIID) contain histone fold motifs (HFMs).

66 mals carrying a liver-specific transcription factor II D (TFIID) defect in transcription initiation.

67 Transcription factor II D (TFIID) is a multiprotein complex that nucle

68 , and the TATA binding protein transcription factor II D (TFIID) were examined in human epidermal ker

69 periments using purified PRC1, transcription factor II D (TFIID), and Mediator indicate that PRC1 blo

70 cificity protein 1, transcription initiation factor II-D, and p-RNA polymerase II, resulting in the r

71 ed that UPF3B (i) interacts with the release factors, (ii) delays translation termination and (iii) d

72 -acetyltransferase) and TFIID (Transcription factor-IID)-dependent mechanisms of transcriptional acti

73 nerve growth factor and insulin-like growth factor II, either alone or in various combinations.

74 ce that SYT-SSX1 induces insulin-like growth factor II expression in fibroblast cells.

75 ore the hypothesis that reduced prothrombin (factor II [FII]) levels in SCD will limit vaso-occlusion

76 en ovalbumin upstream promoter transcription factor II for the DR1 sites in the proximal promoters of

77 rotein S deficiency, 0.42% (0.12%-0.53%) for factor II G202010A, 0.25% (0.12%-0.53%) for factor V G16

78 ies and genotyping of factor V Leiden (FVL), factor II G20210A (FII), and methylenetetrahydrofolate r

79 mbin, protein C, protein S, factor V G1691A, factor II G20210A) and determined the incidence of sympt

80 imprinting (LOI) of the insulin-like growth factor II gene (IGF2) in tumours.

81 omic imprinting (LOI) of insulin-like growth factor II gene (IGF2) involves abnormal activation of th

82 imprinting (LOI) of the insulin-like growth factor II gene (IGF2) is an epigenetic alteration that r

83 Human insulin-like growth factor II gene (IGF2) is overexpressed, and its imprinti

84 The insulin-like growth factor II gene (Igf2) is paternally expressed in the fet

85 alteration affecting the insulin-like growth factor II gene (IGF2), is found in normal colonic mucosa

86 imprinting (LOI) of the insulin-like growth factor II gene (Igf2), which shows aberrant activation o

87 14 SNPs for the MTHFR gene, the Coagulation Factor II gene and the Coagulation Factor V gene.

88 The human insulin-like growth factor II gene is regulated in a development-dependent m

89 Loss of imprinting of insulin-like growth factor-II gene (IGF2) and/or loss of heterozygosity at t

90 imprinting (LOI) of the insulin-like growth factor-II gene (IGF2), leading to abnormal activation of

91 imprinting (LOI) of the insulin-like growth factor-II gene (IGF2), leading to biallelic rather than

92 imprinting (LOI) of the insulin-like growth factor-II gene (IGF2).

93 We observed LOI of the insulin-like growth factor-II gene in twelve of twenty-seven informative col

94 The insulin-like growth factor-II gene lies within the 11p15.5 chromosomal locus

95 h hormone receptors, and insulin-like growth factor II genes.

96 f a soluble neuregulin isoform, glial growth factor II (GGF2), to developing rat muscles alters termi

97 erential localization of insulin-like growth factor II, guanine deaminase, peripherin, early growth r

98 The general transcription factor II H (TFIIH) is a major actor of both nucleotide

99 anscription/DNA repair factor, transcription factor II H (TFIIH) that catalyzes the unwinding of a da

100 As a component of transcription factor II H (TFIIH), XPD is involved in DNA unwinding du

101 (NAIP); and p44, a subunit of transcription factor II H (TFIIH).

102 coding for p53, p57, and insulin-like growth factor II, have been reported in adrenal tumors.

103 dation gene and the transcription initiation factor II-I (TFII-I) are components of a novel member of

104 GTF2I-like repeats 4 and 6 of transcription factor II-I (TFII-I) exhibit modest DNA binding properti

105 e transcription factor general transcription factor II-I (TFII-I).

106 ate Mkx In particular, general transcription factor II-I repeat domain-containing protein 1 (Gtf2ird1

107 port the importance of general transcription factor II-I repeat domain-containing protein 1 (GTF2IRD1

108 omolog of human GTF2I (general transcription factor II-I), which encodes BAP-135, a target for Bruton

109 actor alpha (TNF-alpha), insulin-like growth factor II (IGF II), and parathyroid hormone-related pept

110 is strongly inhibited by insulin-like growth factor II (IGF II).

111 d carries mature 7.5-kDa insulin-like growth factor II (IGF-II) and at least 12 different high molecu

112 N-myc2 and insulin-like growth factor II (IGF-II) are coordinately overexpressed in the

113 lucagon, proinsulin, and insulin-like growth factor II (IGF-II) bind to and are degraded by IDE.

114 The insulin-like growth factor II (IGF-II) gene is located within the region of

115 The insulin-like growth factor II (IGF-II) gene is maternally imprinted in most

116 ells that do not produce insulin-like growth factor II (IGF-II) grow slowly in pure cultures but have

117 a bilateral injection of insulin-like growth factor II (IGF-II) into the dorsal hippocampus of rats o

118 Insulin-like growth factor II (IGF-II) is a major embryonic growth factor be

119 Insulin-like growth factor II (IGF-II) mRNA-binding protein 3 (IMP3) is emer

120 CRD-BP is also known as insulin-like growth factor II (IGF-II) mRNA-binding protein-1.

121 a member of a family of insulin-like growth factor II (IGF-II) mRNA-binding proteins (IMPs), is expr

122 he short-term effects of insulin-like growth factor II (IGF-II) on extraocular muscle morphometry and

123 ith both IL-3 and either insulin-like growth factor II (IGF-II) or stem cell growth factor (SCF).

124 Since insulin-like growth factor II (IGF-II) receptors facilitate the delivery of

125 ation of the polypeptide insulin-like growth factor II (IGF-II) reverses all these deficits.

126 stemic administration of insulin-like growth factor II (IGF-II), a polypeptide that crosses the blood

127 within this domain: (a) insulin-like growth factor II (IGF-II), an important autocrine growth factor

128 growth factor I (IGF-I), insulin-like growth factor II (IGF-II), and their binding proteins (IGFBPs),

129 nown PLAGL2 target gene, insulin-like growth factor II (IGF-II), was greatly diminished in the presen

130 raction of a fragment of insulin-like growth factor II (IGF-II), with the IGF-II binding site on the

131 endogenous expression of insulin-like growth factor II (IGF-II).

132 endogenous expression of insulin-like growth factor II (IGF-II).

133 ning acid hydrolases and insulin-like growth factor II (IGF-II).

134 tter also interacts with insulin-like growth factor II (IGF-II).

135 st prevalent of which is insulin-like growth factor II (IGF-II).

136 The insulin-like growth factor II (IGF-II)/mannose 6-phosphate (Man-6-P) recepto

137 IGF2R gene, encoding the insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor (IGF2R),

138 n the rat, administering insulin-like growth factor II (IGF-II, also known as IGF2) significantly enh

139 nt studies indicate that insulin-like growth factor-II (IGF-II) acts as an autocrine differentiation

140 er, the up-regulation of insulin-like growth factor-II (IGF-II) expression is a predominant feature o

141 ical role of circulating insulin-like growth factor-II (IGF-II) in adult humans is poorly understood.

142 Insulin-like growth factor-II (IGF-II) is an embryonic growth promoter and c

143 ate cancer, up-regulates insulin-like growth factor-II (IGF-II) mRNA and protein levels.

144 IMP-3, a member of the insulin-like growth factor-II (IGF-II) mRNA-binding protein (IMP) family, is

145 The insulin-like growth factor-II (IGF-II) receptor (IGF2R) regulates the level

146 annose-6-phosphate (M6P)/insulin-like growth factor-II (IGF-II) receptor is a multifunctional membran

147 ium and are defective in insulin like growth factor-II (IGF-II) secretion, an autocrine/paracrine fac

148 get of let-7 regulation, insulin-like growth factor-II (IGF-II).

149 iver regeneration [ALR], insulin-like growth factor-II [IGF-II], and hepatocyte growth factor [HGF])

150 ese include the gene for insulin-like growth factor II (IGF2) and H19, which show abnormal imprint-sp

151 Extensive methylation of insulin-like growth factor II (IGF2) and hypermethylated in cancer-1 (HIC-1)

152 elic regulation of mouse insulin-like growth factor II (Igf2) as a model, we demonstrate that CTCF bi

153 Insulin-like growth factor II (IGF2) belongs to a family of growth factors t

154 utionary analyses of the insulin-like growth factor II (IGF2) gene in teleost fishes.

155 imprinting (LOI) of the insulin-like growth factor II (IGF2) gene is associated with a predispositio

156 The insulin-like growth factor II (IGF2) gene is paternally expressed and is sur

157 eated sequences, loss of insulin-like growth factor II (IGF2) imprinting, abrogation of silencing of

158 of genomic imprinting of insulin-like growth factor II (IGF2) is a hallmark of many human neoplasms.

159 Insulin-like growth factor II (Igf2) is maternally imprinted in normal tissu

160 The gene for insulin-like growth factor II (IGF2) is normally expressed from the paternal

161 17 have higher levels of insulin-like growth factor II (IGF2) mRNA and protein in the frontal cortex

162 bryos, the expression of Insulin-like growth factor II (IGF2) plays a key role in maternal-fetal inte

163 ind and target exogenous insulin-like growth factor II (IGF2) to the prelysosomes where it is degrade

164 y true for the imprinted Insulin-like Growth Factor II (IGF2), a key regulator of embryonic growth in

165 was not linked to LOI of insulin-like growth factor II (IGF2), which was found in 2 of 10 (20%) BWS p

166 r the imprinted gene for insulin-like growth factor II (IGF2).

167 t maternal allele of the insulin-like growth factor-II (IGF2) gene, silencing of the normally active

168 nation protein 1, MYOD1; insulin-like growth factor II, IGF2; tumor suppressor candidate 33, N33; ade

169 High levels of insulin-like growth factor II (IGFII) mRNA expression are detected in many h

170 promotes translation of insulin-like growth factor II (IGFII) mRNA.

171 NAGLU and a fragment of insulin-like growth factor II (IGFII) was prepared for endocytosis by the ma

172 complexes also colocalize with transcription factor IID in these cells, further supporting a general

173 olling the expression of insulin-like growth factor-II in a kinase-independent manner.

174 en ovalbumin upstream promoter transcription factor II) in the Wolffian duct mesenchyme became inters

175 ave any effect on EGF or insulin-like growth factor-II-induced growth of human BACs.

176 Thus, while the host factor Ii is not essential for the formation of the M. t

177 Finally, addition of transcription factor IIS is known to cause polymerase blocked at a thy

178 en ovalbumin upstream promoter-transcription factor II, is an orphan nuclear receptor of the steroid/

179 that restoring the normal levels of clotting factors II, IX, and X while simultaneously restoring fib

180 of TF to an electronic milieu consisting of factors II, IX, X, VII, VIIa, V, and VIIII, and the anti

181 e growth factor I and/or insulin-like growth factor II levels or secretion.

182 Factor II levels, chromogenic factor X levels, and proth

183 zing mannose 6-phosphate/insulin-like growth factor II (M-6-P/IGF-II) receptor binding to the surface

184 the mannose 6-phosphate/insulin-like growth factor-II (Man-6-P/IGF-II) receptor.

185 peptidase, receptors for insulin-like growth factor-II/Man-6-phosphate and transferrin, and a glycopr

186 The insulin-like growth factor II/mannose 6-phosphate receptor (IGF2R) carries o

187 The insulin-like growth factor II/mannose 6-phosphate receptor (IGF2R) interacts

188 ) binding domains of the insulin-like growth factor II/mannose 6-phosphate receptor (Man-6-P/IGF2R),

189 A soluble form of the insulin-like growth factor II/mannose 6-phosphate receptor (sIGF-II/MPR) is

190 drate recognition by the insulin-like growth factor II/mannose 6-phosphate receptor are predicted by

191 The insulin-like growth factor II/mannose 6-phosphate receptor is a multifunctio

192 -P) binding sites of the insulin-like growth factor-II/mannose 6-phosphate receptor (IGF-II/MPR) have

193 The insulin-like growth factor-II/mannose 6-phosphate receptor (IGF-II/MPR) is a

194 human cation-independent insulin-like growth factor-II/mannose 6-phosphate receptor (IGF-IIR) with IG

195 e recycling pathways for insulin-like growth factor-II/mannose 6-phosphate receptor (MPR) and transfe

196 lated populations of the insulin-like growth factor-II/mannose 6-phosphate receptor, the transferrin

197 ent MPR (CD-MPR) and the insulin-like growth factor II/MPR (IGF-II/MPR), recognize a diverse populati

198 However, high levels of insulin-like growth factor II mRNA are detected in many human tumors includi

199 Vg1 RNA binding protein, Insulin-like growth factor II mRNA binding protein 1, Coding region determin

200 Endogenous insulin-like growth factor II mRNA derived from the P3 as well as transfecte

201 H19 RNA and insulin-like growth factor II mRNA were up-regulated significantly in non-ne

202 ophila melanogaster homologue insulin growth factor II mRNA-binding protein (IMP).

203 cardiolipin antibodies, factor VII mutation, factor II mutation, and antiphospholipid antibodies.

204 to p32, a component of the ASF/SF2 splicing factors, (ii) ORF P protein colocalizes with spliceosome

205 tes were detected in the insulin-like growth factor II P3 promoter.

206 The insulin/insulin-like growth factor (IIS) pathway comprises a single receptor, DAF-2.

207 ombin (proteins induced by vitamin K absence-factor II, PIVKA-II), and the percentage of undercarboxy

208 ming growth factor-beta, insulin-like growth factor-II, plasminogen, and urokinase-type plasminogen a

209 in-like growth factor I, insulin-like growth factor II, platelet-derived growth factor, basic fibrobl

210 l growth factors such as insulin-like growth factor-II, platelet-derived growth factor-A, and transfo

211 which in turn decreased insulin-like growth factor II production and autocrine signaling.

212 tion of an Sp1-dependent insulin-like growth factor II promoter construct in MCF-7E cells compared wi

213 gulability, including factor V Leiden R506G, factor II (prothrombin) G20210A, and methylenetetrahydro

214 Transcription factor IIS provided roughly the same level of read-throu

215 Insulin-like growth factor II receptor (IGF2R) is a multifunctional cell sur

216 ulated the expression of insulin-like growth factor II receptor (IGF2R), which may play a part in the

217 The insulin-like growth factor II receptor (IGFIIR) gene has been identified as

218 The insulin-like growth factor II receptor (IGFIIR) has been implicated as a tum

219 dent mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF-II receptor) undergoes const

220 the mannose-6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) dependent on CREG glycosy

221 The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) forms oligomeric structur

222 the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) plays a critical role in

223 Mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) tumor suppressor- gene mu

224 the mannose-6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) with high affinity, sugge

225 the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGFIIR) as a binding protein for

226 the mannose 6-phosphate/insulin-like growth factor II receptor (Man-6-P/IGF-II receptor) and its lig

227 the mannose 6-phosphate/insulin-like growth factor II receptor (Man-6-P/IGF2R) is considered importa

228 the mannose 6-phosphate/insulin-like growth factor II receptor and the TGF-beta type I and II recept

229 the mannose 6-phosphate/insulin-like growth factor II receptor and the transforming growth factor be

230 dent mannose 6-phosphate/insulin-like growth factor II receptor cytoplasmic domain required for effic

231 eat polymorphisms of the insulin-like growth factor II receptor gene (IGF2R) in oral cancer risk.

232 uences, such as BAX, the insulin-like growth factor II receptor IGFIIR, and even the mismatch repair

233 the mannose 6-phosphate/insulin-like growth factor II receptor in GUS transport across the BBB in ne

234 the mannose 6-phosphate/insulin-like growth factor II receptor, the TGF-beta type I and II receptors

235 protein-coupled receptor (GPCR) coagulation factor II receptor-like 1 (F2rl1, previously known as Pa

236 Two loci, factor II receptor-like 3 (F2RL3) and G-protein-coupled

237 the mannose 6-phosphate/insulin-like growth factor II receptor.

238 SHV of the expression of insulin-like growth factor-II receptor (IGF-IIR), a mannose-6-phosphate rece

239 The mannose 6-phosphate/insulin-like growth factor-II receptor (M6P/IGFIIR) plays an important role

240 face mannose 6-phosphate/insulin-like growth factor II receptors (M6P/IGF2R) bind and target exogenou

241 approximately 9 nM) when the shared factor X/factor II site was blocked by excess factor II (4 microM

242 to examine the effects of the transcription factor IID-specific subunit TAF130p (TAF145p) upon the T

243 xtracts, including subunits of transcription factor IID (TFIID) (yeast TAFII20 [yTAFII20], yTAFII60,

244 n, we have examined changes in transcription factor IID (TFIID) and cofactor required for Sp1 activat

245 ther TBP-containing complexes [Transcription Factor IID (TFIID) and TFIIIB] were also found to dimini

246 uced transcriptional activity, transcription factor IID (TFIID) binding is not observed.

247 d conformational change in the transcription factor IID (TFIID) complex.

248 r 9 (TAF9), a component in the transcription factor IID (TFIID) complex.

249 General transcription factor IID (TFIID) is a multisubunit protein complex inv

250 The multisubunit transcription factor IID (TFIID) is an essential component of the euka

251 Transcription factor IID (TFIID) nucleates transcription initiation co

252 Transcription factor IID (TFIID) plays a central role in regulating th

253 The general transcription factor IID (TFIID) plays a central role in the initiatio

254 Transcription factor IID (TFIID) plays a key role in regulating eukary

255 The largest transcription factor IID (TFIID) subunit, TBP-associated factor 1 (TAF

256 Transcription factor IID (TFIID), the TBP-containing coactivator that

257 ntial component of the general transcription factor IID (TFIID), which nucleates assembly of the prei

258 F1), causing a derepression of transcription factor IID (TFIID)-driven transcription.

259 y a parallel pathway involving transcription factor IID (TFIID).

260 iated factor (TAF) subunits of transcription factor IID (TFIID).

261 ants show reduced affinity for transcription factor IID (TFIID).

262 largest component of the basal transcription factor IID (TFIID).

263 factor 4alpha (HNF4alpha) and transcription factor IID (TFIID).

264 vator Zta recruits the general transcription factors IID (TFIID) and IIA (TFIIA) to promoter DNA and

265 imulated by the EC rescue factor stimulatory factor II (TFIIS/SII).

266 Transcription factors IIS (TFIIS) and IIF (TFIIF) are known to stimula

267 tightly associated with human transcription factor IID than hTAF(II)130 is associated with hTAF(II)2

268 lactin, osteopontin, and insulin-like growth factor-II), that can discriminate between disease-free a

269 geting of VP22 is independent of other viral factors, (ii) the carboxyl terminus of VP22 is required

270 triking and includes the insulin-like growth factor II, the cisplatin resistance-associated protein,

271 , 2.54; 23 studies, I(2) = 29%), coagulation factor II (thrombin) gene (F2) mutation G20210A (rs17999

272 e dinucleotide (CpG) site within coagulation factor II (thrombin) receptor-like 3 (F2RL3) was recentl

273 (M values) of cg03636183 in the coagulation factor II (thrombin) receptor-like 3 gene (F2RL3) (M = -

274 mbin receptors on platelets F2R (coagulation factor II (thrombin) receptor; PAR1) and GP5 (glycoprote

275 ecorrin-2 to factor II), and iron insertion (factor II to siroheme).

276 he CREs but also by recruiting transcription factor IID to the insulin promoter via its interaction w

277 ch contains a portion of insulin-like growth factor II, to create an active, chimeric enzyme with hig

278 d stress-sensing insulin/insulin-like growth factor (IIS)/TOR signalling network, which ameliorates a

279 Autocrine gastrins, insulin-like growth factor-II, transforming growth factor-alpha, and endocri

280 nvolved in the common pathway were depleted (factor II, V, X), which corresponded to increased plasma

281 ing from 2.63 (95% CI, 1.61 to 4.29) for the factor II variant to 9.44 (95% CI, 3.34 to 26.66) for an

282 randomized to 4F-PCC (containing coagulation factors II, VII, IX, and X and proteins C and S) or plas

283 n inability to synthesize active coagulation factors II, VII, IX, and X, although there is growing ev

284 rotein, and a number of coagulation factors (factors II, VII, IX, X and proteins S and C).

285 els of fibrinogen, and increased activity of factor II, VIII, and X.

286 ced in trigeminal ganglia by neuron-specific factors, (ii) viral or virus-induced factors participate

287 esentative sequence of helix D of heparin co-factor II, was demonstrated to be potent against agronom

288 ts, revealed that oxidized Co(III) or Ni(II)-factor-II were equally good substrates, whereas Co(II)-p

289 like growth factor-I and insulin-like growth factor-II were low and remained low throughout the 7-day

290 n binds to mRNA encoding insulin-like growth factor II, which has been found to be overexpressed in H

291 equence, and is not rescued by transcription factor IIS, which is in contrast to pol II blockage by a